Neurogenic Orthostatic Hypotension
📧 Sign up to get email alerts when something new happens for Neurogenic Orthostatic Hypotension.
Sign up freeTop drugs studied for this disease
-
FDA approval · 2021-02-18FDA Approved: DROXIDOPA — Original Application (Sun Pharmaceutical Industries, Inc.)
FDA approved Sun Pharmaceutical Industries' original application for droxidopa, granting approval of a generic version of the drug. Droxidop…
-
FDA approval · 2020-10-01FDA Approved: MIDODRINE HYDROCHLORIDE — Original Application (Xiromed, LLC)
FDA approved Midodrine Hydrochloride under an original Abbreviated New Drug Application (ANDA) for Xiromed, LLC.
-
FDA approval · 2019-11-04FDA Approved: MIDODRINE HYDROCHLORIDE — Supplemental Application (Mylan Pharmaceuticals Inc.)
FDA approved a supplemental application for Midodrine hydrochloride submitted by Mylan Pharmaceuticals Inc.
-
CLINICAL_TRIALS trial_result · 2019-10-29Clinical Trial Update: Effect of L-Dihydroxyphenylserine (L-DOPS) on Falls in Patients With Neurogenic Orthostatic Hypotension (NOH) [Phase 2]
Phase 2 trial evaluating L-Dihydroxyphenylserine (L-DOPS) for reducing falls in patients with neurogenic orthostatic hypotension, Parkinson …
-
CLINICAL_TRIALS trial_result · 2019-04-05Clinical Trial Update: Efficacy and Safety of Midodrine and Atomoxetine for Neurogenic OH [Phase 4]
Phase 4 trial evaluating the efficacy and safety of midodrine and atomoxetine for neurogenic orthostatic hypotension has been completed.
- Want full summaries, importance scores, and drug timelines? Upgrade to Plus or Pro.
-
CLINICAL_TRIALS trial_result · 2017-04-17Clinical Trial Update: Treatment and Prognosis of Neurogenic Orthostatic Hypotension : A Prospective Randomized Study [Phase 4]
A Phase 4 randomized trial reports on treatment and prognosis for neurogenic orthostatic hypotension, with completed results available.
-
FDA approval · 2017-02-10FDA Approved: NORTHERA — Supplemental Application (Lundbeck Pharmaceuticals LLC)
The FDA approved a supplemental application for Northera (droxidopa) submitted by Lundbeck Pharmaceuticals LLC. This action approves changes…
-
CLINICAL_TRIALS trial_result · 2016-01-08Clinical Trial Update: A Clinical Study of Patients With Symptomatic NOH to Assess Sustained Effects of Droxidopa Therapy [Phase 3]
Phase 3 study of droxidopa in symptomatic neurogenic orthostatic hypotension, including participants with Parkinson's disease, multiple syst…
-
FDA approval · 2015-08-24FDA Approved: NORTHERA — Supplemental Application (Lundbeck Pharmaceuticals LLC)
The FDA approved a supplemental application for NORTHERA (droxidopa) from Lundbeck Pharmaceuticals LLC.
-
FDA approval · 2015-08-19FDA Approved: NORTHERA — Supplemental Application (Lundbeck Pharmaceuticals LLC)
The FDA approved a supplemental application for NORTHERA (droxidopa) submitted by Lundbeck Pharmaceuticals LLC.
-
CLINICAL_TRIALS trial_result · 2015-05-21Clinical Trial Update: Study to Assess the Benefit of Midodrine in the Treatment of Patients With Neurogenic Orthostatic Hypotension [Phase 4]
Phase 4 trial update evaluating the benefit of midodrine in neurogenic orthostatic hypotension has completed with results posted.
-
CLINICAL_TRIALS trial_result · 2015-05-12Clinical Trial Update: A Study for Patients With Neurogenic Orthostatic Hypotension [Phase 4]
Phase 4 trial update for patients with neurogenic orthostatic hypotension; study completed with results posted in 2015.
-
FDA approval · 2014-09-30FDA Approved: NORTHERA — Supplemental Application (Lundbeck Pharmaceuticals LLC)
The FDA approved a supplemental application for NORTHERA (droxidopa) submitted by Lundbeck Pharmaceuticals LLC.
-
CLINICAL_TRIALS trial_result · 2014-06-09Clinical Trial Update: Study To Assess The Clinical Benefit Of Droxidopa In Subjects With Chronic Fatigue Syndrome [Phase 2]
Phase 2 study evaluating droxidopa for chronic fatigue syndrome with orthostatic symptoms was terminated; results were posted in 2014.
-
CLINICAL_TRIALS trial_result · 2014-05-20Clinical Trial Update: Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) [Phase 3]
This update reports the Phase 3 results of droxidopa in patients with symptomatic neurogenic orthostatic hypotension.
-
CLINICAL_TRIALS trial_result · 2014-05-20Clinical Trial Update: A Two Part Study (306A/306B) to Assess Droxidopa in Treatment of NOH in Patients With Parkinson's Disease [Phase 3]
Phase 3 two-part trial (306A/306B) evaluated droxidopa for neurogenic orthostatic hypotension in Parkinson's disease; the study completed an…
-
CLINICAL_TRIALS trial_result · 2014-05-16Clinical Trial Update: A Clinical Study for Patients With Neurogenic Orthostatic Hypotension (NOH) Using Droxidopa [Phase 3]
Phase 3 clinical trial of droxidopa for neurogenic orthostatic hypotension has completed; results have been posted.
-
CLINICAL_TRIALS trial_result · 2014-05-16Clinical Trial Update: Open-Label Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) [Phase 3]
Open-label Phase 3 study of droxidopa in neurogenic orthostatic hypotension has completed and results were posted in 2014.
-
CLINICAL_TRIALS trial_result · 2014-04-21Clinical Trial Update: Clinical Study of Droxidopa in Patients With Neurogenic Orthostatic Hypotension (NOH) (Droxi-304) [Phase 3]
Phase 3 clinical study of droxidopa (NOH) completed; results posted in 2014 for patients with neurogenic orthostatic hypotension and related…
-
FDA approval · 2014-02-18FDA Approved: NORTHERA — Original Application (Lundbeck Pharmaceuticals LLC)
The FDA approved NORTHERA (droxidopa) through an original NDA submitted by Lundbeck Pharmaceuticals LLC. It is indicated for the treatment o…
-
CLINICAL_TRIALS trial_result · 2008-10-01Clinical Trial Update: Fipamezole in Neurogenic Orthostatic Hypotension [Phase 2]
Phase 2 clinical trial update on fipamezole for symptomatic neurogenic orthostatic hypotension, with associated conditions including Parkins…